Table 1 Baseline characteristics (randomized population)
Low-dose SC cohort (n = 39) | High-dose IV cohort (n = 52) | |||
|---|---|---|---|---|
Placebo (n = 13) | Crenezumab (n = 26) | Placebo (n = 17) | Crenezumab (n = 35) | |
Age (years), mean (SD) | 68.9 (8.3) | 66.7 (9.5) | 69.8 (7.7) | 71.4 (7.1) |
Sex, female (%) | 61.5 | 53.8 | 35.3 | 68.6 |
MMSE score, mean (SD) | 22.3 (2.4) | 21.5 (2.4) | 20.5 (2.2) | 20.8 (2.3) |
MMSE 20–26 (mild), % | 92.3 | 73.1 | 58.8 | 60.0 |
APOEε4 carriers, % | 92.3 | 84.6 | 70.6 | 68.6 |
ADAS-Cog12 score, mean (SD) | 28.9 (7.4) | 29.4 (9.7) | 34.5 (11.1) | 31.2 (9.9) |
CDR-SB score, mean (SD) | 4.3 (1.5) | 4.2 (2.1) | 5.9 (1.9) | 4.9 (2.0) |
ADCS-ADL score, mean (SD) | 66.8 (6.8) | 65.4 (9.5) | 64.5 (8.2) | 66.8 (7.4) |
SUVR (cerebellar gray reference) | 1.9 (0.3) | 1.8 (0.3) | 1.8 (0.3) | 1.7 (0.3) |
AChEI and/or memantine use, % | 92.3 | 84.6 | 82.4 | 91.4 |